company? Let’s change
that.
Don't see your company?
Create a company profileBellbrook Labs is a research and development company focusing on advancing drug discovery for human health therapies.
Spectrum CannaLabs is an analytical testing laboratory that provides testing solutions for legal cannabis products.
Bio Adaptives provides natural stem cell therapy solutions to create scientifically valid, research-based natural wellness solutions.
We optimize your health with precision nourishment. All your nutrients, scientifically optimized to your body’s daily needs, are provided through a diverse variety of delicious entrees, made fresh, locally, & daily. Conveniently available or delivered for less than your average takeout. Enjoy precision nourishment every meal, every day.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ), is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases—often with limited or no options—so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again. Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals has a significant corporate presence in Palo Alto, CA, Philadelphia, PA and Oxford, England, with manufacturing facilities in Ireland and Italy. We maintain a highly collaborative culture where employees focus on how they can be successful and accomplish positive results by exemplifying the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. Together, we are more than 3,100 experts, analysts, specialists, advocates, scientists and professionals all with diverse backgrounds and perspectives. Working together, we are proud to support patients, innovate and bring new medicines to market. For more information, please see our website at www.jazzpharma.com and follow us on Twitter at @JazzPharma. For information on fraudulent schemes involving our company name and recruitment, please visit https://bit.ly/2J1EjMA. For guidelines on engaging with Jazz on social media, please visit https://bit.ly/2OaMOuq.
Tetherex Pharmaceuticals operates in the healthcare industry focusing on biotechnology business.
InCube Labs is a life sciences research lab focused on developing medical breakthroughs that dramatically improve patient outcomes.
Founded in 1967, Riverside Research is a not-for-profit organization chartered to advance scientific research for the benefit of the US government and in the public interest. Through our open innovation concept, we invest in multi-disciplinary research and development and encourage collaboration to accelerate innovation and advance science. Riverside Research conducts independent research in machine learning, trusted systems, optics and photonics, electromagnetics, plasma physics, radio frequency systems, and biomedical engineering. We move science from the laboratory to the field by building teams of recognized experts who deliver effective, high-value solutions and services to our customers. From public service to national security, we aspire to be a valued partner through our unwavering commitment to innovative and mission-focused solutions.
Capio Biosciences focuses on delivering high-value oncology diagnostics that can help inform patient care decisions and improve outcomes.
Kintara Therapeutics is a developer of novel cancer therapies for patients with unmet medical needs.
Lentechs is a medical device company that develops a novel soft bifocal contact lens.
Carmine Therapeutics, headquartered in Cambridge MA, is pioneering a new class of non-viral gene therapies based on red blood cell extracellular vesicles, combined with proprietary payloads. In June 2020, Carmine inked a research alliance with Takeda Pharmaceuticals worth up to $900 million to develop non-viral gene therapies for 2 targets. Carmine has also been named one of the FierceBiotech’s Fierce 15 Biotech companies of 2020 and was also awarded the Bristol-Myers Squibb "Golden Ticket". Carmine was founded in 2019 by EVX Ventures, Professors Harvey Lodish (Whitehead, MIT), Minh Le and Jiahai Shi. Professor Lodish, who was a founding member of several successful biotech companies that include Genzyme and Millennium Pharmaceuticals, is also Chair of the Scientific Advisory Board of Carmine. For more information, visit www.carminetherapeutics.com Media Relations [email protected] Investor Relations [email protected]
At Ultragenyx, we fundamentally believe that taking real impactful action to care for the needs of patients and our people is always the right thing to do. To achieve this goal, our vision is to lead the future of rare disease medicine. For us, this means going where other biopharma companies won’t go – challenging the status quo and creating a new model that advances our field so more patients and caregivers can benefit from life-changing treatments. We do this by following the science, applying a novel rapid development approach, making innovative medicines at fair and reasonable prices, and creating a collaborative ecosystem to reach patients in ways that are most meaningful for them.
Pplatform for expediting Laboratory Outsourcing and Scientific Procurement
Medical devices for molecular diagnostics, we specialize in self or assisted sampling, and transport of biological samples
We are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. While enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. Cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. Our goal is nothing less than to develop curative cell-based therapies for solid tumor cancers.
Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we hope to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to quickly and efficiently build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for new cures—to dramatically improve patients’ lives.
Apertura is a biotechnology company opening opportunities in gene therapy for treating debilitating diseases with limited options. We are pioneering next-generation AAV gene therapies by simultaneously engineering capsids, regulatory elements, and payloads to overcome current limitations in genetic medicine. Founded on technologies from the Broad Institute and Harvard University, and with support from Deerfield Management Company, we are located at the Cure in New York City.
Revalesio Corporation, located in Tacoma, WA, is partnering with leaders in biomedical research around the globe to harness the benefits of fluid modification via turbulent Taylor-Couette-Poiseuille (TCP) flow. Revalesio’s patented application of fluid cavitation within a
At Lykos Therapeutics, our mission is to transform the way mental health is treated. We aspire to challenge the status quo through the development of novel therapies and therapeutic approaches to treat mental health conditions. With 30+ years of experience researching psychedelic-assisted therapies, we remain focused on following rigorous science from which we can develop and commercialize novel treatment options. Founded in 2014 by the non-profit Multidisciplinary Association for Psychedelic Studies (“MAPS”), we are a for-profit public benefit corporation (“PBC”). As a PBC, we consider the impact of our decisions on society just as we think about financial implications. Everything we do is looked at through a public benefit lens. To learn more, visit us at www.lykospbc.com.